Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07269041 · ClinicalTrials.gov registry record · Phase 1

Immune Tolerance Induction After Liver Transplantation

A Phase 1 study of End Stage Liver DIsease and Liver Transplantation, sponsored by University of California, Los Angeles.

Recruiting
Registry status
Phase 1
Development phase
12
Enrollment target
1
Study location

NCT07269041: Recruiting Phase 1 study of End Stage Liver DIsease and Liver Transplantation, sponsored by University of California, Los Angeles.

NCT07269041 is a Phase 1 study of End Stage Liver DIsease and Liver Transplantation that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 12 participants, below the 491-participant average among 16 other End Stage Liver DIsease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07269041, a Phase 1 study of End Stage Liver DIsease and Liver Transplantation, is actively recruiting participants, sponsored by University of California, Los Angeles.

RECRUITING
Registry status
Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

This clinical trial is being conducted to help liver transplant recipients safely discontinue toxic immunosuppressive drugs years after surgery. Lifelong use of these drugs is the current standard, but they come with life-threatening side effects. UCLA has pioneered this "Delayed Tolerance" approach, achieving success in numerous kidney recipients now living drug-free. The process uses a conditioning regimen followed by donor stem cell infusion to retrain the immune system to accept the liver as "self."

Primary Outcome

The percentage of subjects who successfully discontinue all liver transplant immunosuppressant medications at 12 months after HSPC infusion.

Conditions Studied

End Stage Liver DIsease Liver Transplantation Immune Tolerance Chimerism Immune Tolerance/Drug Effects Graft Survival Hematopoietic Stem Cell Immunosuppression After Liver Transplantation Immunosuppression Disorders

Interventions

  • BIOLOGICAL Donor Hematopoietic Stem and Progenitor Cell Infusion

Study Locations (1)

California

  • UCLA Health 200 Medical Plaza - Los Angeles

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2026-02-20
Est. Completion 2033-01
Phase Phase 1
University of California, Los Angeles

897 total trials

What NCT07269041 shows while recruiting

NCT07269041 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 491-participant average among 16 other End Stage Liver DIsease trials with a reported enrollment target (98% lower).

The record links to 9 conditions, with End Stage Liver DIsease appearing as the primary indexed condition, and to 1 intervention - of which Donor Hematopoietic Stem and Progenitor Cell Infusion is the first listed.

NCT07269041 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT07269041 about?

NCT07269041 is a clinical study titled "Immune Tolerance Induction After Liver Transplantation". This clinical trial is being conducted to help liver transplant recipients safely discontinue toxic immunosuppressive drugs years after surgery. Lifelong use of these drugs is the current standard, but they come with life-threatening side effects. UCLA has pioneered this "Delayed Tolerance" approach...

What is the current status of trial NCT07269041?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-02-20. Estimated completion is 2033-01.

What conditions does trial NCT07269041 study?

This clinical trial studies the following conditions: End Stage Liver DIsease, Liver Transplantation, Immune Tolerance, Chimerism, Immune Tolerance/Drug Effects.

What interventions are being tested in trial NCT07269041?

The interventions under investigation include: Donor Hematopoietic Stem and Progenitor Cell Infusion (BIOLOGICAL).

Who is sponsoring clinical trial NCT07269041?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07269041 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for End Stage Liver DIsease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07269041's enrollment target sits among peer trials

12 15th of 16 higher than 1 of 16 other End Stage Liver DIsease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other End Stage Liver DIsease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07269041

Source: ClinicalTrials.gov NCT07269041, the US trial registry maintained by the National Library of Medicine. NCT07269041 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.